SEER
Seer, Inc. NASDAQ$1.95
Mkt Cap $110.0M
52w Low $1.65
39.5% of range
52w High $2.41
50d MA $1.84
200d MA $1.99
P/E (TTM)
-1.6x
EV/EBITDA
-1.2x
P/B
0.5x
Debt/Equity
0.1x
ROE
-28.4%
P/FCF
-2.3x
RSI (14)
—
ATR (14)
—
Beta
1.60
50d MA
$1.84
200d MA
$1.99
Avg Volume
382.9K
About
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to se…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | -0.32 | -0.29 | +9.4% | 2.08 | -15.4% | -17.3% | -16.8% | -13.5% | -11.1% | -11.5% | — |
| Nov 6, 2025 | AMC | -0.32 | -0.32 | +0.0% | 2.16 | -0.9% | -3.2% | -3.2% | -4.2% | -3.7% | -5.6% | — |
| Aug 6, 2025 | AMC | -0.39 | -0.33 | +15.4% | 2.06 | +0.5% | -2.4% | +11.7% | +7.3% | +6.8% | +5.3% | — |
| May 13, 2025 | AMC | -0.37 | -0.34 | +8.1% | 1.92 | +9.9% | +9.9% | +8.3% | +7.8% | +7.8% | +8.9% | — |
| Feb 27, 2025 | AMC | -0.31 | -0.34 | -9.7% | 2.20 | +0.0% | -4.5% | -6.4% | -7.3% | -7.3% | -9.1% | — |
| Nov 6, 2024 | AMC | -0.29 | -0.34 | -17.2% | 2.07 | -2.4% | +7.2% | +15.0% | +8.2% | +9.2% | +11.6% | — |
| Aug 8, 2024 | AMC | -0.36 | -0.35 | +2.8% | 1.73 | -0.6% | -0.6% | -1.7% | -1.7% | -4.0% | -2.3% | — |
| May 8, 2024 | AMC | -0.31 | -0.32 | -3.2% | 2.23 | -6.7% | -7.6% | -10.3% | -10.8% | -3.1% | -4.0% | — |
| Feb 29, 2024 | AMC | -0.35 | -0.28 | +20.0% | 1.82 | -1.1% | +0.0% | +5.5% | +4.9% | +10.4% | +14.3% | — |
| Nov 7, 2023 | AMC | -0.38 | -0.33 | +13.2% | 1.72 | -4.1% | -5.2% | -6.1% | -9.3% | -7.6% | -3.5% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4 | Canaccord Genuity | Initiates | Buy | $4 | $2.03 | $2.05 | +1.0% | -3.9% | — | — | — | — |
| Aug 13 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $1.70 | $1.70 | +0.0% | +0.0% | -2.4% | -0.6% | -0.6% | -2.4% |
| Feb 21 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $4.44 | $4.14 | -6.8% | -11.3% | -10.6% | -11.5% | -16.2% | -11.9% |
| Jan 4 | BofA Securities | Downgrade | Neutral → Underperform | — | $5.85 | $5.52 | -5.6% | -22.1% | -27.5% | -21.4% | -13.8% | -3.1% |
| Nov 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $6.79 | $7.16 | +5.4% | +20.3% | +26.4% | +15.2% | +20.9% | +9.9% |
| Aug 11 | JP Morgan | Downgrade | Overweight → Neutral | — | $13.31 | $12.28 | -7.7% | -19.7% | -10.5% | -11.3% | -18.0% | -18.0% |
| Aug 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $13.31 | $12.28 | -7.7% | -19.7% | -10.5% | -11.3% | -18.0% | -18.0% |
| May 5 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $9.04 | $8.91 | -1.4% | -0.4% | +2.8% | -11.1% | -14.7% | -22.3% |
| Mar 1 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $15.32 | $14.85 | -3.1% | -10.0% | -9.7% | -14.0% | -18.4% | -21.7% |
| Feb 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $15.41 | $15.89 | +3.1% | +3.9% | +1.6% | -8.2% | -16.9% | -16.7% |
Recent Filings
8-K · 8.01
!! High
Seer, Inc. -- 8-K 8.01: Material Event / Announcement
Seer received a revised unsolicited acquisition proposal from Bradley Radoff and Michael Torok on April 24, 2026, though the offer remains non-binding and highly contingent, leaving the company's strategic options open.
Apr 27
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
SEER received an unsolicited acquisition proposal from Bradley L., requiring board review but carrying no certainty of deal completion, creating uncertainty that could drive near-term stock volatility.
Apr 13
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Seer successfully defended its core protein enrichment patent against Bruker's challenge, protecting key intellectual property and competitive moat that validates its proprietary technology differentiation.
Mar 30
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
Seer's appointment of Computershare as transfer agent signals institutional infrastructure maturity and may facilitate future equity issuances or public company operational scaling.
Mar 16
8-K
Seer, Inc. -- 8-K Filing
Seer reports full year 2025 financial results and provides 2026 guidance, indicating the proteomics company's operational performance and management's outlook for continued business development.
Feb 26
8-K · 1.01
!! High
Seer, Inc. -- 8-K 1.01: Material Agreement
Seer, Inc. entered into a material agreement with Computershare Trust Co., likely involving transfer agent services or equity plan administration, which supports operational infrastructure for shareholder management.
Feb 26
Data updated apr 27, 2026 12:39am
· Source: massive.com